Overview of Phytoral

Quick Facts: Phytoral (Ketoconazole)

Property	Description
Active ingredient	Ketoconazole (INN)
Form	Tablet, Cream, Shampoo, Lotion, Ointment
Pharmacological class	Azole Antifungal (Imidazole derivative)
Common purpose	To suppress the growth of fungal and yeast infections
Origin	Synthetic compound

What Type of Medicine is Phytoral (Ketoconazole)?

Phytoral is a medicinal preparation containing the active component Ketoconazole, which is definitively classified as a synthetic Azole Antifungal Agent. It is specifically identified as an imidazole antifungal class member, defining its fundamental pharmacological role in suppressing the proliferation of fungi and yeasts. Ketoconazole is entirely synthetic in origin, chemically based on the imidazole ring structure, and is utilized as a monotherapy, meaning it contains this single active pharmaceutical ingredient. Phytoral is recognized for its broad-spectrum activity, which supports its role as a standard agent in antifungal therapy.

Active Ingredient and Available Forms

The therapeutic effectiveness of Phytoral is derived solely from Ketoconazole, and this single-ingredient preparation is supplied in multiple dosage form(s) suitable for different applications. The medication is available as an oral formulation (tablet) for internal use, as well as various topical formulations including cream, ointment, shampoo, and lotion. This range of forms allows the drug to be administered either via the oral route for systemic purposes or applied directly topically to address localized conditions affecting the skin or scalp. For the patient, this provides delivery options that can be tailored to the specific location of the fungal infection.

General Purpose and Mechanism Summary

The core purpose of Phytoral is to combat and control infections caused by fungi and yeasts throughout the body. The drug accomplishes this by acting as a fungistatic agent, effectively halting the ability of the infectious organisms to multiply and spread. This specific action is rooted in the drug’s biochemical capability to selectively interfere with the fungal cell's necessary production of ergosterol, a crucial structural component of the fungal cell membrane, thereby weakening the organism's viability. This mechanism is effective against common pathogenic fungi, underscoring its therapeutic role.

Regulatory References

EMA referral on Ketoconazole

What side effects are possible with Phytoral?

Possible Side Effects and Safety Information

The safety profile of Phytoral (Ketoconazole) is strictly differentiated by its route of administration: systemic (oral tablets) versus local (topical creams, shampoos, and gels). Official regulatory documents classify potential adverse reactions based on this distinction.

Systemic Safety Profile (Oral Tablet)

Systemic use is associated with serious, clinically significant adverse reactions. The main concern documented in regulatory labeling is Hepatotoxicity (liver injury), including reports of fatal outcomes and cases requiring liver transplantation. The oral tablet also carries warnings regarding Cardiac Disorders, specifically the risk of QT prolongation and potentially life-threatening ventricular arrhythmias, such as Torsades de pointes, when co-administered with certain drugs. Endocrine adverse reactions, such as Adrenal Insufficiency, are also documented, alongside common effects affecting Gastrointestinal and Nervous System Disorders (e.g., nausea, headache).

Safety Restrictions: The oral tablet is strictly contraindicated in individuals with acute or chronic liver disease. Co-administration with specific drugs is prohibited due to the risk of cardiac dysrhythmias.

Topical Safety Profile (Cream, Shampoo)

Adverse reactions associated with topical administration are predominantly localized to the application site. Regulatory classification defines effects by frequency:

Classification	Examples of Reactions
Common	Application site burning sensation, erythema, or pruritus (itching).
Uncommon	Contact dermatitis, skin exfoliation, or rash.

Serious reactions like Anaphylaxis and other severe hypersensitivity reactions, though rare, have been reported for both systemic and topical formulations. For specific populations, caution is advised for use during pregnancy or lactation, and the safety of topical formulations has not been established for children under 12 years of age.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Phytoral (ketoconazole) describes specific signs of overexposure and mandates immediate action due to the potential for serious outcomes.

Documented Manifestations and Actions

Classification	Official Regulatory Statement
Documented Manifestations	Overdose exposure may result in an exacerbation of adverse effects, including nausea, vomiting, and diarrhea. More severe cases can present with signs of acute liver injury (e.g., jaundice, fatigue, or anorexia), which is recognized as a potentially fatal complication.
Supportive Management	No specific antidote is known for ketoconazole overdose. Treatment is restricted to symptomatic and supportive measures. For oral overexposure, procedures such as gastric lavage and the administration of activated charcoal are officially described for use within the first hour of ingestion.
Emergency Action Required	Immediate medical attention must be sought. Regulators mandate that emergency services should be contacted if the affected individual has collapsed, experiences a seizure, has trouble breathing, or cannot be awakened. Close clinical monitoring, including checks of blood pressure and electrolyte balance, is necessary following overexposure.

This information strictly defines the official response to overdose based on the drug's known toxicity profile as described in government-authorized prescribing information.

Therapeutic Uses of Phytoral

What Phytoral Treats: Main Uses and Benefits

Phytoral (ketoconazole) is commonly used to help with symptoms related to physical discomfort across therapeutic domains where additional symptomatic support is needed, primarily as an antifungal agent. Topical formulations (cream and shampoo) are applied in addressing various conditions presenting with systemic or localized discomfort caused by fungal or yeast infections.

These conditions involving episodic or fluctuating manifestations include common skin infections such as ringworm (tinea corporis), jock itch (tinea cruris), athlete's foot (tinea pedis), and a skin condition where patches change color (tinea versicolor). It also plays a role in managing symptoms of seborrheic dermatitis. The application may assist with easing the overall symptom burden, and is considered relevant for easing the overall symptom load.

“The medication contributes to improved comfort during periods of heightened symptoms.”

The use of this medication is relevant for easing symptoms related to inflammatory or irritative states, such as the flaking, scaling, and itching symptoms that interfere with daily comfort. It assists with maintaining functional stability during difficult episodes.

Quick Fact: Supports Easing Flaking and Itching

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Phytoral?

The use of Phytoral (Ketoconazole) is governed by specific regulatory eligibility rules that vary between the systemic (oral tablet) and topical (cream, shampoo) formulations.

Contraindicated Populations

Patients with acute or chronic liver disease are absolutely contraindicated from using the oral tablet formulation due to the risk of severe hepatotoxicity, as documented in official labeling. Furthermore, any patient with a known hypersensitivity to ketoconazole or any component of the medicine is prohibited from using any formulation.

Conditional and Restricted Use

Use of the oral tablet is generally restricted to serious conditions where alternative antifungal therapies are not available or tolerated.

Age-Related Eligibility

The oral tablet's safety and efficacy are not established in children under 12 years of age. For certain topical products, regulatory standards indicate a typical minimum age of 12 years.

Reproductive Status

The oral tablet is often contraindicated or not recommended for women who are pregnant or breastfeeding, with minimal systemic absorption noted for the topical forms.

What should I know about interactions with other medicines?

Phytoral Interactions with other medicines and products

Phytoral's interaction profile is officially defined by its effects on drug metabolism and absorption, leading to specific restrictions documented by regulatory authorities.

Interaction Scope

Category	Official Regulatory Statement Summary
Medicinal products with documented interactions	CYP3A4 substrates (e.g., certain statins, antiarrhythmics, oral benzodiazepines, calcium channel blockers); CYP3A4 inducers (e.g., Rifampin, St. John's Wort); P-glycoprotein substrates; Gastric acid-reducing agents (e.g., Antacids, PPIs); Alcohol.
Mechanistic basis of interactions	Strong inhibition of CYP3A4 (reducing clearance of co-administered drugs) and inhibition of P-glycoprotein (increasing exposure of co-administered drugs).
Timing-based interaction rules	Antacids (e.g., aluminum hydroxide) must be administered at least 1 hour before or 2 hours after the Phytoral tablet due to the need for stomach acid for absorption.
Population-specific interaction notes	The co-administration of Colchicine is specifically contraindicated in patients with pre-existing renal or hepatic impairment.

Interaction-Related Restrictions

Official interaction statements:

Co-administration is contraindicated with numerous CYP3A4 substrates (e.g., Lovastatin, Simvastatin, Oral Midazolam, Cisapride, Quinidine, Pimozide), as the resulting elevated plasma levels pose a significant risk of toxicity.
Co-administration with potent CYP3A4 inducers (e.g., St. John’s Wort) should be avoided as they reduce the concentration of Phytoral in the blood.
The concomitant use of alcohol is restricted due to the potential for a disulfiram-like reaction.

These official regulatory statements establish the structure of the interaction profile, classifying numerous drugs as contraindicated to mitigate the risk of severe adverse events, and imposing timing constraints for acid-reducing agents to ensure adequate absorption.

Mechanism of Action

The action of Phytoral (Ketoconazole) is defined by its interference with a structure-building pathway unique to fungal organisms, resulting in cellular failure and a halt in proliferation.

Molecular Targeting of Ergosterol Synthesis

The drug's primary mechanism involves the inhibition of the fungal enzyme Lanosterol 14alpha-demethylase (CYP51A1), a component in the fungal Ergosterol Biosynthesis Pathway. By binding to the enzyme's active site, Ketoconazole halts the conversion of lanosterol into ergosterol, which is required for the fungal cell membrane's structure and fluidity.

Physiological Consequence: Cell Membrane Destabilization

The resulting depletion of ergosterol and the simultaneous accumulation of toxic sterol intermediates compromises the fungal cell's outer barrier. This loss of structural integrity increases membrane permeability, causing intracellular components to leak out and impairing the cell's ability to regulate transport. This molecular effect prevents the organism from proliferating, leading to the drug’s fungistatic physiological effect.

️ Mechanistic Constraints

The reach of this mechanism is governed by physicochemical properties, such as the drug's poor ability to penetrate the Central Nervous System (CNS), constraining its action in that compartment. Furthermore, the mechanism can be overridden in fungal strains that develop acquired resistance, often through mutations in the CYP51A1 enzyme or the upregulation of efflux pumps that actively expel the drug.

Dosage and Administration Information

Phytoral (ketoconazole) is administered via two primary routes, each with distinct usage parameters: the oral tablet for systemic purposes and various topical formulations (cream, shampoo, foam) for localized conditions. The administration instructions define the method, timing, and duration of use.

Oral Tablet Administration

The oral tablet is dosed at 200 mg once daily (QD) for adults, with the ability to increase the regimen to a maximum of 400 mg daily. A condition for use is that the tablet must be taken with a meal to ensure optimal absorption. If antacids are used, the oral dose must be separated by 1 to 2 hours, or taken with an acidic beverage to facilitate dissolution.

For pediatric patients ge 2 years, the oral dose is weight-based, typically 3.3 to 6.6 mg/kg. If a dose is missed, the instruction is to skip the dose if it is near the next scheduled time, and never to double the dose.

Topical Administration and Protocol

Topical forms are applied once daily (QD) or twice daily (BID), depending on the specific formulation. When using the shampoo for the scalp or skin, a procedural step is to ensure the product remains on the affected area for 3 to 5 minutes before being rinsed off. Treatment durations are generally time-bound, lasting from 2 to 6 weeks for topical use, or potentially up to six months for systemic oral use.

Recent Clinical Evidence

Research evidence / Overview of studies for Phytoral

1. Evidence for Use in Tinea Pedis (Athlete's Foot)

Research examining this topical formulation for Athlete's Foot has been evaluated in short-term, randomized controlled trials (RCTs). These studies compared the topical formulation against inactive vehicles or other established treatments. Researchers focused on tracking changes in outcomes related to physical discomfort, such as itching and scaling, and assessing the fungal infection's status through laboratory tests. Findings describe patterns observed in the studies, such as the proportion of participants with measurements consistent with fungal clearance and those whose clinical signs were measured as resolved. This evidence is relevant in research contexts involving fluctuating symptoms. However, research findings suggest the available evidence is limited, as follow-up durations were restricted in the main trials. Long-term effects are not fully established, and results apply only to the studied populations.

2. Evidence for Use in Seborrheic Dermatitis

Studies have explored different topical formulations—shampoo and cream—in conditions characterized by fluctuating manifestations. Research includes RCTs comparing the product to an inactive vehicle or other treatments. These studies monitored patient-reported outcomes describing perceived discomfort and used investigator assessments to monitor specific signs, such as flaking, redness, and scalp itching. Research highlights changes measured during the short treatment period (typically two to four weeks). Beyond the initial phase, the drug was observed in observational settings evaluating daily-life functioning for up to a year. The certainty remains low regarding long-term maintenance strategies, as comparative evidence is lacking, and data for certain groups (like infants) remain insufficient.

3. Evidence in Subgroups and Uncertainties

Research for Tinea Corporis, Tinea Cruris, and Tinea Versicolor utilized clinical efficacy trials focused on evaluating measurements related to fungal clearance. For these, the evidence is limited, and quality varies. Research exploring long-term outcomes is generally restricted; the durability of the observed response and recurrence patterns are not fully established. Results apply only to the populations studied, primarily healthy adults and adolescents. Data for subgroups such as very young children or older adults with complex conditions are still emerging or insufficient.

Frequently Asked Questions (FAQ)

Common questions about Phytoral (FAQ)

Q: What Phytoral is used for besides its main purpose?

Official labeling restricts the Phytoral oral tablet only to the treatment of certain serious systemic fungal infections when alternative medications are not available or tolerated. Outside of these primary approved uses, the active ingredient is described in research contexts for addressing conditions like Cushing's syndrome when other options have failed.

Q: What is the difference between Phytoral and over-the-counter options?

Regulatory authorities designate the oral tablet for specific severe systemic fungal infections due to the potential for serious risks, such as liver injury. This strict restriction means its use is reserved for situations where the potential benefit is deemed to outweigh the risk. Conversely, the topical forms are approved for local, non-life-threatening skin conditions and are not associated with these systemic risks.

Q: Is it true that Phytoral takes a long time to start working?

Official documents describe that the full treatment period is necessary to ensure the infection is cleared, which can range from a few weeks for topical use up to six months or longer for systemic use. Studies track final measured outcomes over a period of weeks to months, and official documents indicate treatment should be continued for the full prescribed time, even if symptoms are measured as improving early.

Q: Is Phytoral used for long-term or short-term treatment?

The duration of use described in regulatory documents depends on the formulation and the condition under treatment. Topical preparations, like creams and shampoos, are generally used for defined short periods (e.g., 2–6 weeks). The oral tablet, used for serious systemic infections, can be continued for a longer duration and may extend for up to six months or more, subject to medical monitoring.

Q: Can Phytoral cause changes in mood or behavior?

Official safety reports have included rare or post-marketing adverse events such as 'mood or mental changes' and 'confusion'. Furthermore, changes in mood, like depression, have been noted in connection with reports of adrenal insufficiency, which is a documented serious risk associated with the oral tablet.

Q: What is the research evidence for using Phytoral in children?

For the oral tablet, official prescribing information states that safety and effectiveness are established for children aged 2 years and older, provided appropriate dosing is used. However, safety and effectiveness are not established for children under 2 years of age. For some topical products, effectiveness is established for individuals 12 years of age and older.

Q: How long does Phytoral stay in your system after you stop using it?

Official pharmacokinetic data shows that the medicine’s concentration in the body declines in two phases: initially rapidly, and then more slowly thereafter. Due to its strong effect on the metabolism of other medicines, regulatory documents recommend avoiding certain contraindicated drugs for up to one week after the oral tablet is stopped.

Q: Is Phytoral considered a strong medicine?

Regulatory authorities classify the oral tablet for use only in serious, severe systemic fungal infections and advise its use when other effective therapies are not available. This limited indication and the risk profile described in the Boxed Warning govern its use. Regulatory authorities restrict the oral tablet’s use due to the potential for severe adverse reactions.

Q: Why do some people say Phytoral is hard to get?

The oral tablet formulation is strictly restricted by regulatory bodies to treating serious systemic fungal infections due to the potential for severe adverse reactions, including liver injury and heart problems. The limited, reserved indication and the serious risk profile documented in the label are key factors that govern its highly regulated distribution and availability.

Q: Can Phytoral be taken by older adults?

Regulatory documents for some topical formulations note that no overall differences in safety or effectiveness were observed between older individuals (aged 65 and over) and younger subjects in studies. However, official information suggests that a greater sensitivity in some older individuals cannot be ruled out.

Q: Can I use Phytoral if I have celiac disease or gluten sensitivity?

Official prescribing information for the oral tablet lists its inactive ingredients, which typically include components like lactose monohydrate and microcrystalline cellulose. These ingredients are published to provide information for checking potential sensitivities, though no specific warnings for celiac disease or gluten sensitivity are documented in the regulatory labeling.

Q: Does Phytoral interact with birth control pills?

Phytoral is documented as a strong inhibitor of the enzyme CYP3A4. Many hormonal birth control pills are metabolized by this enzyme. Official regulatory documents list numerous drugs that are contraindicated or require caution because of this inhibition mechanism, which may affect the concentration of co-administered drugs.

Q: Is it true that Phytoral can cause sensitivity to the sun?

Official safety information, including post-marketing reports collected by regulatory bodies, includes photosensitivity (an increased sensitivity to the sun) as a potential adverse reaction to the product.

Q: How does Phytoral affect the immune system?

The drug’s mechanism is fungistatic, meaning it targets and inhibits fungal growth directly. However, official labeling for the oral tablet also notes a risk of adrenal insufficiency, which can impact the body's natural production of cortisol. Some topical formulations are specifically indicated for use in immunocompetent adults (those with a normally functioning immune system).

Q: What is the reason Phytoral might be considered 'high-risk' by some communities?

The oral tablet carries specific and serious warnings from regulatory bodies regarding the potential for severe adverse reactions. These include a Boxed Warning concerning severe liver injury (hepatotoxicity) and risks related to the heart (QT prolongation and arrhythmias). The oral tablet's use is restricted due to these documented risks.

Q: Does Phytoral lose effectiveness over time?

The potential for a medicine to lose effectiveness is generally tied to acquired resistance by the target organism. Regulatory documents for some topical formulations state that the development of resistance to the active ingredient has not been reported in clinical studies.

Q: Can men and women use Phytoral for the same conditions?

The primary approved purposes of the drug are not specific to gender. However, regulatory documents for the oral tablet list specific adverse reactions in males, such as breast enlargement, and apply specific restrictions for women who are pregnant or breastfeeding.

Q: Do people report gaining or losing weight while on Phytoral?

Official safety information for the oral tablet lists weight loss as a symptom associated with serious adverse reactions. Specifically, weight loss is noted in connection with potential liver problems and the risk of adrenal insufficiency (hypocortisolism).

How should Phytoral be stored and disposed of?

How to Store and Dispose of Phytoral?

The storage and disposal of Phytoral (ketoconazole) must follow strict regulatory guidelines to maintain drug stability and ensure safety.

Labeled storage temperature requirements:	Store at controlled room temperature (20 C to 25 C / 68 F to 77 F); excursions permitted between 15 C and 30 C.
Light/moisture protection requirements:	Must be protected from excessive heat and moisture.
Handling requirements:	Do not freeze the medicine. Store in the original container and keep it tightly closed.
Child-protection storage requirements:	Keep out of the sight and reach of children and pets.
Disposal instructions:	Do not flush unused medicine down a toilet or drain. Utilize an official drug take-back program as the preferred method.

If a take-back program is unavailable, discard the product in the household trash after mixing it with an unappealing substance (like coffee grounds or cat litter) and sealing the mixture in a bag. These requirements prohibit environmental disposal via wastewater and secure the product from accidental access.

Phytoral